Profil
Brian Burkavage is Chief Financial & Accounting Officer at Damora Therapeutics, Inc. starting in 2026.
Former positions include Chief Accounting Officer at IO Biotech, Inc. from 2022 to 2025, Controller at Passage Bio, Inc. from 2020 to 2021, and Director-Financial Planning & Analysis at Aclaris Therapeutics, Inc. from 2017 to 2020.
Education includes undergraduate and graduate degrees from the University of Notre Dame.
Postes actifs de Brian Burkavage
| Sociétés | Poste | Début |
|---|---|---|
| DAMORA THERAPEUTICS, INC. | Directeur Financier/CFO | 01/05/2026 |
Anciens postes connus de Brian Burkavage
| Sociétés | Poste | Fin |
|---|---|---|
| IO BIOTECH, INC. | Comptroller/Controller/Auditor | 12/12/2025 |
| PASSAGE BIO, INC. | Comptroller/Controller/Auditor | 01/01/2021 |
| ACLARIS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2020 |
Formation de Brian Burkavage
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
University of Notre Dame
University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel drug candidates for immuno-inflammatory diseases | Health Technology |
Passage Bio, Inc.
Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Galecto, Inc.
Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
IO Biotech, Inc.
IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
















